Figure 2

Effects of Smac/DIABLO with chemotherapeutic drugs or TRAIL on cell viability. (A), MDA-MB-453 cells were transiently transfected with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and treated with tamoxifen (100 nm), doxorubicin (100 nM), paclitaxel (100 nM) or TRAIL (75 nM) for 36 h. Cell viability was measured by XTT assay. Data represent mean ± SE. *, #, & = significantly different from the respective control at P < 0.05. (B), MDA-MB-468 cells were transiently transfected with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and treated with tamoxifen (100 nM), doxorubicin (100 nM), paclitaxel (100 nM) or TRAIL (75 nM) for 36 h. Cell viability was measured by XTT assay. Data represent mean ± SE. *, #, & = significantly different from the respective control at P < 0.05. (C), MDA-MB-453 cells were transiently transfected with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and treated with paclitaxel (100 nM), doxorubicin (100 nM), etoposide (100 nM), tamoxifen (100 nm), irradiation (5 Gy) or TRAIL (75 nM) for 36 h. Apoptosis was measured by DAPI staining. Data represent mean ± SE. *, #, & = significantly different from the respective control at P < 0.05. (D), MDA-MB-468 cells were transiently transfected with plasmids expressing Smac/DIABLO full length, Smac Δ55 or neo for 24 h, and treated with paclitaxel (100 nM), doxorubicin (100 nM), etoposide (100 nM), tamoxifen (100 nm), irradiation (5 Gy) or TRAIL (75 nM) for 36 h. Apoptosis was measured by DAPI staining. Data represent mean ± SE. *, #, & = significantly different from the respective control at P < 0.05.